DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Information source: Biogen
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Intervention: Interferon beta-1a (Avonex) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Biogen

Official(s) and/or principal investigator(s):
Biogen-Idec Investigator, Principal Investigator, Affiliation: Biogen


This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.

Clinical Details

Official title: A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX«, MS Subjects Na´ve to Treatment, and Healthy Control Subjects

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: Changes in bioanalytical measures after receiving therapy for 3 to 6 months


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria: Healthy Control Subjects (Group 1)

- Must be in general good health.

- Must not have received interferons in the past.

All MS Subjects

- Clinical or laboratory-supported diagnosis of relapsing remitting MS (McDonald et al,

criteria numbers 1-4).

- Either on AVONEX® or treatment-naïve.

- Have an EDSS score between 0. 0 and 5. 5, inclusive.

Exclusion Criteria:

- History of severe allergic or anaphylactic reaction or hypersensitivity to human

albumin, to any interferon, to other components of the drug formulation.

- History of intolerance to acetaminophen, ibuprofen, naproxen, and aspirin that would

preclude the use of at least one of these during the study.

- History of any clinically significant (as determined by the investigator) cardiac,

endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease.

- History of malignancy.

- The presence of any significant medical condition or psychiatric illness not due to

MS that, in the investigator's opinion, would interfere with therapy

- History of uncontrolled seizures within the 3 months prior to enrollment.

- History of suicidal ideation or an episode of severe depression within the 3 months

prior to enrollment.

- Serious local infection (e. g., cellulitis, abscess) or systemic infection (e. g.,

pneumonia, septicemia) within 8 weeks prior to enrollment.

- Positive for human immunodeficiency virus (HIV), hepatitis C antibody (HCV) or

positive for hepatitis B surface antigen (HbsAg) at screening. Other inclusion and exclusion criteria apply as per protocol

Locations and Contacts

Additional Information

Starting date: November 2002
Last updated: June 3, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017